Saspiphi
Engineered bacteriophage therapeutics targeting harmful bacteria for antimicrobial treatment development
Highlights
- Young companyFounded 2024
- New on EvolcAdded 2026-11-09
About Saspiphi
SASPiPhi is developing SASPject, a platform that uses engineered bacteriophages to deliver a gene encoding a toxic protein into target bacteria, aiming for rapid, selective bacterial elimination. Development programmes target Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii.
SASPiPhi Limited is a UK company founded in 2024 and headquartered in Cambridge.
Product: SASPject is a bacteriophage-based platform for developing targeted antimicrobial therapies.
Jobs at Saspiphi
Leadership
- Andrew Armour · CFOSource: company website
- Sarah Knightley · COOSource: company website
More biotech & pharma companies
Scancell
Clinical-stage immunotherapy developer for difficult-to-treat cancers, using Immunobody and Moditope platformsNew on EvolcScripta Therapeutics
Drug discovery platform using transcription factor mapping and AI models to find neurodegenerative disease therapiesYoung companyNew on EvolcSENTINAL4D
AI models and imaging data tools for biotech and pharmaceutical R&D teams studying cell morphology and drug responsesYoung companyNew on EvolcSequoia Genetics
Human genetics research and analysis for pharma, biotech, investors, and academic institutions developing medicinesYoung companyNew on EvolcSeren Plus
Wholesale supplier of prescription medicines and aesthetic products to pharmacies and clinics across the UKNew on EvolcShafi Consultancy
Clinical trial statistical programming and data services for pharmaceutical companies and contract research organizationsNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Hosting
- ApacheHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
